Aclaris Therapeutics Q1 net loss widens on higher R&D spending

Aclaris Therapeutics

07/05/2026 12:06

Overview

US biopharma firm's Q1 revenue rose and beat analyst expectations

Q1 adjusted EPS beat consensus

Net loss widened and missed analyst estimates

Outlook

Aclaris expects top line results from Phase 1b ATI-052 trials in H2 2026

Company plans to initiate Phase 2b ATI-052 program in asthma in Q4 2026

Aclaris expects cash, equivalents and securities to fund operations through end of 2028

Result Drivers

HIGHER ROYALTIES - Revenue increase was primarily driven by higher royalties from Lilly and Sun Pharma license agreements

R&D SPENDING - Research and development expenses rose due to ATI-052 clinical development and ATI-9494 manufacturing costs, partially offset by lower ATI-2138 expenses

HIGHER ADMIN COSTS - General and administrative expenses increased due to higher professional, legal, and personnel expenses

Company press release: ID:nGNX1HxqDy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$2 mln
$1.32 mln (9 Analysts)
Q1 EPS
Beat
-$0.15
-$0.16 (9 Analysts)
Q1 Net Income
Miss
-$19.82 mln
-$19.62 mln (8 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $10.00, about 109.2% above its May 6 closing price of $4.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)